Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention

IntroductionAcetylsalicylic acid (ASA) is a well-known and safe anti-inflammatory. At low-dose, it is prescribed to prevent secondary cardiovascular events in those with pre-existing conditions and to prevent preeclampsia. Little is known about how low-dose ASA affects the immune response. In this s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julie Lajoie, Monika M. Kowatsch, Lucy W. Mwangi, Geneviève Boily-Larouche, Julius Oyugi, Yufei Chen, Makobu Kimani, Emmanuel A. Ho, Joshua Kimani, Keith R. Fowke
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	HIV immune activation (IA) HIV risk aspirin Acetylsalicylic acid inflammation Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/f795b4bc44bb4994bf8fb9117f3c8b69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f795b4bc44bb4994bf8fb9117f3c8b69
record_format	dspace
spelling	oai:doaj.org-article:f795b4bc44bb4994bf8fb9117f3c8b692021-11-18T09:13:38ZLow-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention1664-322410.3389/fimmu.2021.778455https://doaj.org/article/f795b4bc44bb4994bf8fb9117f3c8b692021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.778455/fullhttps://doaj.org/toc/1664-3224IntroductionAcetylsalicylic acid (ASA) is a well-known and safe anti-inflammatory. At low-dose, it is prescribed to prevent secondary cardiovascular events in those with pre-existing conditions and to prevent preeclampsia. Little is known about how low-dose ASA affects the immune response. In this study, we followed women to assess how ASA use modifies T cells immune phenotypes in the blood and at the genital tract.MethodsHIV uninfected women from Kenya were enrolled in this study and followed for one month to assess baseline responses including systemic/mucosal baseline immune activation. Participants then received 81mg of ASA daily for 6 weeks to assess changes to T cell immune activation (systemic and mucosal) relative to baseline levels.ResultsThe concentration of ASA measured in the blood was 58% higher than the level measured at the female genital tract. In the blood, the level of ASA was inversely correlated with the following: the proportion of Th17 expressing HLA-DR (p=0.04), the proportion of effector CD4+ T cells expressing CCR5 (p=0.03) and the proportion of CD8+Tc17 expressing CCR5 (p=0.04). At the genital tract, ASA use correlated with a decreased of activated CD4+T cells [CD4+CCR5+CD161+ (p=0.02) and CD4+CCR5+CD95+ (p=0.001)].ConclusionThis study shows that ASA use impacts the immune response in both the systemic and genital tract compartments. This could have major implications for the prevention of infectious diseases such as HIV, in which the virus targets activated T cells to establish an infection. This could inform guidelines on ASA use in women.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT02079077.Julie LajoieJulie LajoieMonika M. KowatschLucy W. MwangiGeneviève Boily-LaroucheJulius OyugiJulius OyugiJulius OyugiYufei ChenMakobu KimaniEmmanuel A. HoEmmanuel A. HoJoshua KimaniJoshua KimaniJoshua KimaniKeith R. FowkeKeith R. FowkeKeith R. FowkeKeith R. FowkeFrontiers Media S.A.articleHIVimmune activation (IA)HIV riskaspirinAcetylsalicylic acidinflammationImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	HIV immune activation (IA) HIV risk aspirin Acetylsalicylic acid inflammation Immunologic diseases. Allergy RC581-607
spellingShingle	HIV immune activation (IA) HIV risk aspirin Acetylsalicylic acid inflammation Immunologic diseases. Allergy RC581-607 Julie Lajoie Julie Lajoie Monika M. Kowatsch Lucy W. Mwangi Geneviève Boily-Larouche Julius Oyugi Julius Oyugi Julius Oyugi Yufei Chen Makobu Kimani Emmanuel A. Ho Emmanuel A. Ho Joshua Kimani Joshua Kimani Joshua Kimani Keith R. Fowke Keith R. Fowke Keith R. Fowke Keith R. Fowke Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention
description	IntroductionAcetylsalicylic acid (ASA) is a well-known and safe anti-inflammatory. At low-dose, it is prescribed to prevent secondary cardiovascular events in those with pre-existing conditions and to prevent preeclampsia. Little is known about how low-dose ASA affects the immune response. In this study, we followed women to assess how ASA use modifies T cells immune phenotypes in the blood and at the genital tract.MethodsHIV uninfected women from Kenya were enrolled in this study and followed for one month to assess baseline responses including systemic/mucosal baseline immune activation. Participants then received 81mg of ASA daily for 6 weeks to assess changes to T cell immune activation (systemic and mucosal) relative to baseline levels.ResultsThe concentration of ASA measured in the blood was 58% higher than the level measured at the female genital tract. In the blood, the level of ASA was inversely correlated with the following: the proportion of Th17 expressing HLA-DR (p=0.04), the proportion of effector CD4+ T cells expressing CCR5 (p=0.03) and the proportion of CD8+Tc17 expressing CCR5 (p=0.04). At the genital tract, ASA use correlated with a decreased of activated CD4+T cells [CD4+CCR5+CD161+ (p=0.02) and CD4+CCR5+CD95+ (p=0.001)].ConclusionThis study shows that ASA use impacts the immune response in both the systemic and genital tract compartments. This could have major implications for the prevention of infectious diseases such as HIV, in which the virus targets activated T cells to establish an infection. This could inform guidelines on ASA use in women.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT02079077.
format	article
author	Julie Lajoie Julie Lajoie Monika M. Kowatsch Lucy W. Mwangi Geneviève Boily-Larouche Julius Oyugi Julius Oyugi Julius Oyugi Yufei Chen Makobu Kimani Emmanuel A. Ho Emmanuel A. Ho Joshua Kimani Joshua Kimani Joshua Kimani Keith R. Fowke Keith R. Fowke Keith R. Fowke Keith R. Fowke
author_facet	Julie Lajoie Julie Lajoie Monika M. Kowatsch Lucy W. Mwangi Geneviève Boily-Larouche Julius Oyugi Julius Oyugi Julius Oyugi Yufei Chen Makobu Kimani Emmanuel A. Ho Emmanuel A. Ho Joshua Kimani Joshua Kimani Joshua Kimani Keith R. Fowke Keith R. Fowke Keith R. Fowke Keith R. Fowke
author_sort	Julie Lajoie
title	Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention
title_short	Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention
title_full	Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention
title_fullStr	Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention
title_full_unstemmed	Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention
title_sort	low-dose acetylsalicylic acid reduces t cell immune activation: potential implications for hiv prevention
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/f795b4bc44bb4994bf8fb9117f3c8b69
work_keys_str_mv	AT julielajoie lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT julielajoie lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT monikamkowatsch lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT lucywmwangi lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT genevieveboilylarouche lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT juliusoyugi lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT juliusoyugi lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT juliusoyugi lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT yufeichen lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT makobukimani lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT emmanuelaho lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT emmanuelaho lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT joshuakimani lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT joshuakimani lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT joshuakimani lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT keithrfowke lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT keithrfowke lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT keithrfowke lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention AT keithrfowke lowdoseacetylsalicylicacidreducestcellimmuneactivationpotentialimplicationsforhivprevention
_version_	1718421001031647232

Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention

Ejemplares similares